Stocktoria
CHINA PHARMA HOLDINGS, INC. CPHI
CHINA PHARMA HOLDINGS, INC. (CPHI) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $4.1M at a -76.9% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | -0.163 |
| Retained earnings / assets | -1.523 |
| EBIT / assets | -0.104 |
| Equity / liabilities | 2.753 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| CPHI | CHINA PHARMA HOLDINGS, INC. | 4/9 | -3.85 | — | — |
| ATAI | AtaiBeckley Inc. | 4/9 | — | — | — |
| CRVO | CervoMed Inc. | 1/9 | -12.9 | — | — |
| MRKR | Marker Therapeutics, Inc. | 2/9 | — | — | — |
| CAMP | Camp4 Therapeutics Corp | 3/9 | -4.88 | — | — |
| PCYN | PROCYON CORP | 3/9 | 3.03 | — | — |
| ENSC | Ensysce Biosciences, Inc. | — | — | — | — |
About CHINA PHARMA HOLDINGS, INC.
China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products for human use in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection for edema diseases, hypertension, acute renal failure, hyperkalemia, hypercalcemia, and acute drug poisoning; and Candesartan for hypertension. It offers Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and Pseudophedrine Hydrochlorida sustained release tablets, as well as Hepatocyte growth-promoting factors, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. In addition, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection for nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It supplies its products to hospitals and OTC pharmacies through provincial and municipal pharmaceutical logistics companies. The company is based in Haikou, the People's Republic of China.
FAQ
Is CPHI financially healthy?
CHINA PHARMA HOLDINGS, INC.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does CPHI pay a dividend?
No, CHINA PHARMA HOLDINGS, INC. does not currently pay a dividend.
How profitable is CPHI?
In FY2025, CHINA PHARMA HOLDINGS, INC. had a net margin of -76.9% and a return on equity of -14.0%.
Is CPHI a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on CHINA PHARMA HOLDINGS, INC.: a Piotroski F-score of 4/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.